89 related articles for article (PubMed ID: 35948035)
1. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer.
Hester CA; Perri G; Prakash LR; Maxwell JE; Ikoma N; Kim MP; Tzeng CD; Smaglo B; Wolff R; Javle M; Overman MJ; Lee JE; Katz MHG
J Natl Compr Canc Netw; 2022 Aug; 20(8):887-897.e3. PubMed ID: 35948035
[TBL] [Abstract][Full Text] [Related]
2. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
3. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer.
Perri G; Prakash L; Wang H; Bhosale P; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay E; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
Ann Surg; 2021 Apr; 273(4):806-813. PubMed ID: 31274655
[TBL] [Abstract][Full Text] [Related]
4. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience.
Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H
Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
6. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
7. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer.
Perri G; Prakash L; Malleo G; Caravati A; Varadhachary GR; Fogelman D; Pant S; Koay EJ; Herman J; Maggino L; Milella M; Kim M; Ikoma N; Tzeng CW; Salvia R; Lee JE; Bassi C; Katz MHG
Ann Surg Oncol; 2020 Oct; 27(10):3939-3947. PubMed ID: 32266574
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9.
Kim SS; Lee S; Lee HS; Bang S; Han K; Park MS
Radiology; 2022 Jun; 303(3):548-556. PubMed ID: 35258374
[TBL] [Abstract][Full Text] [Related]
9. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
10. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
12. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
Choi M; Heilbrun LK; Venkatramanamoorthy R; Lawhorn-Crews JM; Zalupski MM; Shields AF
Am J Clin Oncol; 2010 Jun; 33(3):257-61. PubMed ID: 19806035
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.
Kamarajah SK; White SA; Naffouje SA; Salti GI; Dahdaleh F
Ann Surg Oncol; 2021 Oct; 28(11):6790-6802. PubMed ID: 33786676
[TBL] [Abstract][Full Text] [Related]
14. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
[TBL] [Abstract][Full Text] [Related]
15. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
[TBL] [Abstract][Full Text] [Related]
16. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
17. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
[TBL] [Abstract][Full Text] [Related]
18. The importance of multimodal therapy in the management of nonmetastatic adenosquamous carcinoma of the pancreas: Analysis of treatment sequence and strategy.
Hue JJ; Katayama E; Sugumar K; Winter JM; Ammori JB; Rothermel LD; Hardacre JM; Ocuin LM
Surgery; 2021 May; 169(5):1102-1109. PubMed ID: 33376004
[TBL] [Abstract][Full Text] [Related]
19. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
